Back to top
more

Royalty Pharma (RPRX)

(Real Time Quote from BATS)

$26.70 USD

26.70
602,593

-0.07 (-0.26%)

Updated Jul 15, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Financial - Miscellaneous Services

Better trading starts here.

Zacks News

Trupanion (TRUP) Reports Q2 Loss, Tops Revenue Estimates

Trupanion (TRUP) delivered earnings and revenue surprises of 21.43% and 3.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

PJT Partners (PJT) Q2 Earnings and Revenues Top Estimates

PJT Partners (PJT) delivered earnings and revenue surprises of 54.69% and 41.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Implied Volatility Surging for Royalty Pharma (RPRX) Stock Options

Investors need to pay close attention to Royalty Pharma (RPRX) stock based on the movements in the options market lately.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Royalty Pharma (RPRX) Q1 Earnings and Revenues Top Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 21.21% and 23.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Owl Rock Capital Corporation (ORCC) Reports Next Week: Wall Street Expects Earnings Growth

Owl Rock Capital Corporation (ORCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MVB Financial (MVBF) Q1 Earnings and Revenues Miss Estimates

MVB Financial (MVBF) delivered earnings and revenue surprises of -65.52% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is PRA Group (PRAA) Down 10.4% Since Last Earnings Report?

PRA Group (PRAA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GBOOY vs. RPRX: Which Stock Is the Better Value Option?

GBOOY vs. RPRX: Which Stock Is the Better Value Option?

GBOOY or RPRX: Which Is the Better Value Stock Right Now?

GBOOY vs. RPRX: Which Stock Is the Better Value Option?

Royalty Pharma (RPRX) Matches Q4 Earnings Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Royalty Pharma (RPRX) Surpasses Q3 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Royalty Pharma (RPRX)

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Phillips Edison & Company, Inc. (PECO) Q3 FFO and Revenues Top Estimates

Phillips Edison & Company, Inc. (PECO) delivered FFO and revenue surprises of 9.43% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Jackson Financial (JXN) Q3 Earnings Expected to Decline

Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.